MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers
Abstract MDM4 is one of the MDM protein family and is generally recognized as the key negative regulator of p53. As a cancer-promoting factor, it plays a non-negligible role in tumorigenesis and development. In this article, we analyzed the expression levels of MDM4 in pan-cancer through multiple da...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-024-01684-z |
| _version_ | 1797276683946950656 |
|---|---|
| author | Jie Liu Jie Yang Qilong Pan Xiangyu Wang Xinyin Wang Han Chen Xiaoling Zheng Qingling Huang |
| author_facet | Jie Liu Jie Yang Qilong Pan Xiangyu Wang Xinyin Wang Han Chen Xiaoling Zheng Qingling Huang |
| author_sort | Jie Liu |
| collection | DOAJ |
| description | Abstract MDM4 is one of the MDM protein family and is generally recognized as the key negative regulator of p53. As a cancer-promoting factor, it plays a non-negligible role in tumorigenesis and development. In this article, we analyzed the expression levels of MDM4 in pan-cancer through multiple databases. We also investigated the correlations between MDM4 expression and prognostic value, immune features, genetic mutation, and tumor-related pathways. We found that MDM4 overexpression is often accompanied by adverse clinical features, poor prognosis, oncogenic mutations, tumor-immune infiltration and aberrant activation of oncogenic signaling pathways. We also conducted transcriptomic sequencing to investigate the effect of MDM4 on transcript levels in colon cancer and performed qPCR to verify this. Finally, we carried out some in vitro experiments including colony formation assay, chemoresistance and senescence-associated β-galactosidase activity assay to study the anti-tumor treatment effect of small molecule MDM4 inhibitor, NSC146109. Our research confirmed that MDM4 is a prognostic biomarker and potential therapeutic target for a variety of malignancies. |
| first_indexed | 2024-03-07T15:31:45Z |
| format | Article |
| id | doaj.art-7846a4dcdbd242d0bdeab46046eb713e |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-03-07T15:31:45Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-7846a4dcdbd242d0bdeab46046eb713e2024-03-05T16:23:55ZengBMCEuropean Journal of Medical Research2047-783X2024-01-0129111710.1186/s40001-024-01684-zMDM4 was associated with poor prognosis and tumor-immune infiltration of cancersJie Liu0Jie Yang1Qilong Pan2Xiangyu Wang3Xinyin Wang4Han Chen5Xiaoling Zheng6Qingling Huang7Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical UniversityDepartment of Endoscopy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical UniversityDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical UniversityDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical UniversityDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical UniversityDepartment of Endoscopy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical UniversityAbstract MDM4 is one of the MDM protein family and is generally recognized as the key negative regulator of p53. As a cancer-promoting factor, it plays a non-negligible role in tumorigenesis and development. In this article, we analyzed the expression levels of MDM4 in pan-cancer through multiple databases. We also investigated the correlations between MDM4 expression and prognostic value, immune features, genetic mutation, and tumor-related pathways. We found that MDM4 overexpression is often accompanied by adverse clinical features, poor prognosis, oncogenic mutations, tumor-immune infiltration and aberrant activation of oncogenic signaling pathways. We also conducted transcriptomic sequencing to investigate the effect of MDM4 on transcript levels in colon cancer and performed qPCR to verify this. Finally, we carried out some in vitro experiments including colony formation assay, chemoresistance and senescence-associated β-galactosidase activity assay to study the anti-tumor treatment effect of small molecule MDM4 inhibitor, NSC146109. Our research confirmed that MDM4 is a prognostic biomarker and potential therapeutic target for a variety of malignancies.https://doi.org/10.1186/s40001-024-01684-zMDM4Pan-cancerPrognostic biomarkerTumor-immune infiltrationInhibitor |
| spellingShingle | Jie Liu Jie Yang Qilong Pan Xiangyu Wang Xinyin Wang Han Chen Xiaoling Zheng Qingling Huang MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers European Journal of Medical Research MDM4 Pan-cancer Prognostic biomarker Tumor-immune infiltration Inhibitor |
| title | MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers |
| title_full | MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers |
| title_fullStr | MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers |
| title_full_unstemmed | MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers |
| title_short | MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers |
| title_sort | mdm4 was associated with poor prognosis and tumor immune infiltration of cancers |
| topic | MDM4 Pan-cancer Prognostic biomarker Tumor-immune infiltration Inhibitor |
| url | https://doi.org/10.1186/s40001-024-01684-z |
| work_keys_str_mv | AT jieliu mdm4wasassociatedwithpoorprognosisandtumorimmuneinfiltrationofcancers AT jieyang mdm4wasassociatedwithpoorprognosisandtumorimmuneinfiltrationofcancers AT qilongpan mdm4wasassociatedwithpoorprognosisandtumorimmuneinfiltrationofcancers AT xiangyuwang mdm4wasassociatedwithpoorprognosisandtumorimmuneinfiltrationofcancers AT xinyinwang mdm4wasassociatedwithpoorprognosisandtumorimmuneinfiltrationofcancers AT hanchen mdm4wasassociatedwithpoorprognosisandtumorimmuneinfiltrationofcancers AT xiaolingzheng mdm4wasassociatedwithpoorprognosisandtumorimmuneinfiltrationofcancers AT qinglinghuang mdm4wasassociatedwithpoorprognosisandtumorimmuneinfiltrationofcancers |